Adaptimmune Therapeutics ADAP reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
Adaptimmune Therapeutics their estimated earnings by 15.38%, reporting an EPS of $-0.3 versus an estimate of $-0.26, which surprised analysts.
Revenue was up $10,000 from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.0, which was followed by a 3.48% increase in the share price the next day.
Here's a look at Adaptimmune Therapeutics's past performance:
| Quarter | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.24 | -0.25 | -0.23 | -0.25 |
| EPS Actual | -0.24 | -0.24 | -0.24 | -0.24 |
| Revenue Estimate | 1.36M | 1.83M | 1.98M | 870.00K |
| Revenue Actual | 3.10M | 434.00K | 1.50M | 1.19M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
